Risk prediction in cutaneous melanoma patients from their clinico-pathological features: superiority of clinical data over gene expression data.

ABSTRACT: Risk assessment in cutaneous melanoma (CM) patients is one of the major challenges in the effective treatment of CM patients. Traditionally, clinico-pathological features such as Breslow thickness, American Joint Committee on Cancer (AJCC) tumor staging, etc. are utilized for this purpose. However, due to advancements in technology, most of the upcoming risk prediction methods are gene-expression profile (GEP) based. In this study, we have tried to develop new GEP and clinico-pathological features-based biomarkers and assessed their prognostic strength in contrast to existing prognostic methods. We developed risk prediction models using the expression of the genes associated with different cancer-related pathways and got a maximum hazard ratio (HR) of 2.52 with p-value ~10^-8 for

SUBMITTER: Arora C 

PROVIDER: S-EPMC7472860 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature